Israel's Kamada plasma-based COVID treatment shows potential in 1/2 trial
In 11 of 12 enrolled patients, symptoms were observed to have improved, and the patients were on average subsequently released in under five days.
Blood collection specialist Niilo Juntunen opens the apheresis machine to remove the kit used to collect convalescent plasma from a recovered coronavirus patient at the Central Seattle Donor Center of Bloodworks Northwest during the coronavirus disease (COVID-19) global outbreak, in Seattle, Washing(photo credit: REUTERS)ByCELIA JEAN
